Unveiling the crucial neuronal role of the proteasomal ATPase subunit gene PSMC5 in neurodevelopmental proteasomopathies

Competing Interest Statement

The Department of Molecular and Human Genetics at Baylor College of Medicine receives revenue from clinical genetic testing completed at Baylor Genetics Laboratory. EEE is a scientific advisory board (SAB) member of Variant Bio, Inc. AT and IW are employees of GeneDx, LLC.

Funding Statement

For this work, SK awarded research grants from the Agence Nationale de la Recherche (ANR) for the project ANR-21-CE17-0005 (UPS-NDDecipher) and as a partner of the European Joint Programme on Rare Diseases (EJP RD) for the project ANR-22-RAR4-0001-01 (UPS-NDDiag), from la Region des Pays de la Loire as part of the National Trajectory program for the project TN_2021_AAP_UPS-NDDECIPHER_INSERM_154550, and from Nantes University Hospital (AOI 2021; grant RC22_0020) for the BioTND-UPS biobank. The EJP RD initiative has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement Number 825575. EK received funding from the German Research Foundation (RTG PRO 2719) and the work was further supported by COST (European Cooperation in Science and Technology) Action ProteoCure CA20113 for EK. The authors are grateful to Robert Beyer and Anne Brandenburg for their excellent technical assistance. FE is a recipient of an I-SITE NExT Junior Talent Chair. SB received financial support from the University Hospital Center (CHU) of Nantes for the BioTND-UPS biobank (PROG/09/72-03). The TND-UPS project led by SB, SK and FE is funded for 3 years through the patronage of the Mutuelles AXA as part of its health program dedicated to supporting innovative research projects in France. This research was supported, in part, by funding from the National Institutes of Health (NIH) grant R01MH101221 to EEE, who is an investigator of the Howard Hughes Medical Institute; from the National Natural Science Foundation of China (grant 82201314) and the Fundamental Research Funds for the Central Universities starting fund (grant BMU2022RCZX038) to T.W.; from the National Institutes of Health and the National Institute of Neurological Disorders and Stroke (NIH-NINDS grant K23NS119666) to S.S.; from the European Reference Networks (ERN) CRANIO and ITHACA to A.M.C-G.; from the ERN on Neurological Diseases ERN-RND to D.G-A.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of CHU de Nantes gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes